
Study proves efficacy of protein conjugate in autoimmune disease
VALANX Biotech has reported successful in vivo results in its lead programme VLX101 for the treatment of a range of autoimmune diseases. The findings demonstrate the potential of VLX101, a novel Interleukin-2 conjugate and the efficacy of the therapeutic approach. Protein drugs hold great… Read More












